With all infants now eligible to receive one dose of the RSV monoclonal antibody product nirsevimab during their first RSV season (October 1 to March 31), Public Health is looking for physician feedback to help to determine how much immunization supply your site would receive this fall. 

We’re taking your vote!

Why it matters: Nirsevimab is the most expensive of all publicly funded immunizations, so it’s important to find the right approach to meet patient needs while minimizing wastage.

Background: On April 1, 2026, all infants became eligible to receive a dose for nirsevimab. A new memo to health care providers lays out when it should be administered:

• Infants born from October 1 to March 31 should receive nirsevimab in the birthing facility before being discharged.
• Infants born between April 1 and September 30 can receive nirsevimab in the fall. Providers should plan to offer nirsevimab in October and November to all infants on their roster who were born between April 1 and September 30.
• Read the full memo.

In October or November, all infants born between April 1^st and September 30^th will be due for a 2‑, 4- or 6‑month appointment and should receive the nirsevimab dose at that time. 

Have your say: How would you like to see nirsevimab distributed to your practice?

For both options providers would be required to register to participate in the RSV nirsevimab immunization program.

• Option 1 – Rotavirus Proxy Model (Data-Driven Approach): The last two years of rotavirus shipping data would be used to calculate an initial allocation that each site would receive. That pre-determined amount of supply would be sent in September, with the opportunity to order and receive additional doses within about a week of re-ordering. 

Strengths vs. Limitations: While a lower administrative burden for physicians than Option 2, this option may not reflect current demand and result in more wastage. 

• Option 2 – Appointment-Based Model (Provider-Driven Allocation): The initial allocation would be calculated based on the number of scheduled appointments for eligible infants in October and November reported to Manitoba Health by each location prior to the season and would also include the opportunity to re-order additional doses as needed after initial distribution in September.

Strengths vs. Limitations: This option requires more clinic administrative time to estimate need, but would more clearly reflect real-time, site-specific demand. However, it would not account for differences in percentage uptake between practices.

What do you think? Learn more about the strengths and limitations associated with each option and let us know what you would prefer. Please respond by July 20.